Citation Impact
Citing Papers
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8 + T cells in NOD mice
2008 StandoutNobel
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
2014
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986–2016
2020
Cancer statistics, 2020
2020 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Engineering precision nanoparticles for drug delivery
2020 Standout
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
2018
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
2017
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
2014
Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
2017
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
A view on drug resistance in cancer
2019 StandoutNature
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
2017
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
2015
Combination cancer immunotherapy and new immunomodulatory targets
2015
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
2016
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
2019 Nature
The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
2010
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer
2018
Immuno-Oncology: Emerging Targets and Combination Therapies
2018
Hepatocellular carcinoma
2021 Standout
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Lung cancer: current therapies and new targeted treatments
2016 Standout
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 Standout
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
2016
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Immunotherapeutic effects of intratumoral nanoplexed poly I:C
2019
Personal neoantigen cancer vaccines
2014
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
2019
The Stages of Type 1A Diabetes
2005
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
2018
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
2015
Engineering patient-specific cancer immunotherapies
2019
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
2016
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
2017
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
2018
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer
2018
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
Comprehensive Integration of Single-Cell Data
2019 Standout
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
2018
Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
Immunogenic peptide discovery in cancer genomes
2015
Cytokines in clinical cancer immunotherapy
2018
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
2005 StandoutNobel
MHCAttnNet: predicting MHC-peptide bindings for MHC alleles classes I and II using an attention-based deep neural model
2020
Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity
2014
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
2014
Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity
2014
Coinhibitory Pathways in Immunotherapy for Cancer
2016
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
2016 StandoutNobel
Immunotherapy Through the Years
2017
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
Galectin-Binding O-Glycosylations as Regulators of Malignancy
2015
Redox-Responsive Polycondensate Neoepitope for Enhanced Personalized Cancer Vaccine
2020
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Peptide-binding specificity prediction using fine-tuned protein structure prediction networks
2023 StandoutNobel
IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy
2018
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
2016 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
2003 StandoutNobel
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
2018
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
2018
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
2001 StandoutNobel
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Neoantigens in cancer immunotherapy
2015 StandoutScience
Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters
2018
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
2017
Therapeutic cancer vaccines
2015
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Works of Patrick A. Ott being referenced
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
2012
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
2017
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma
2019
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
2013
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
2016
Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy
2020
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
2016
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
2017
Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties
2013
Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies
2018
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
2017
Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function
2013
Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells
2003
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
2016
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
2015
Combination immunotherapy: a road map
2017
Talimogene Laherparepvec for the Treatment of Advanced Melanoma
2016
The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention.
2013
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
2018
Hair depigmentation as an indicator of durable response to CTLA-4 therapy.
2010
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
2016
HLA-Binding Properties of Tumor Neoepitopes in Humans
2014
Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028.
2017
Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028)
2017
A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.
2014
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
2015
Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma
2015
Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.
2017
A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab
2015
A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.
2015
Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions
2017
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.
2015
Small-Molecule Protein Kinase Inhibitors and Their Effects on the Immune System: Implications for Cancer Treatment
2011
Towards personalized, tumour-specific, therapeutic vaccines for cancer
2017